Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Almirall ( (ES:ALM) ) just unveiled an update.
Almirall’s Annual Report on Remuneration of Directors for 2024 highlights a successful year driven by its dermatological portfolio, particularly products like Ilumetri, Wynzora, and Ebglyss. The company introduced a new Directors’ Remuneration Policy, including a Performance Shares Plan for the CEO, aimed at aligning with market best practices and ensuring flexibility in executive compensation. This strategic move is designed to address shareholder concerns and enhance the company’s ability to attract top talent, potentially impacting its market positioning positively.
More about Almirall
Almirall, S.A. is a pharmaceutical company based in Barcelona, specializing in dermatological products. It operates primarily in Europe and has a focus on treatments for skin conditions such as psoriasis and atopic dermatitis.
YTD Price Performance: 13.30%
Average Trading Volume: 3,485
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €1.94B
For detailed information about ALM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue